Decoy Therapeutics (DCOY) Cash from Financing Activities (2015 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Cash from Financing Activities of $6.1 million for Q4 2025, up 5775.68% year-over-year from $103341.4 in Q4 2024, and up 3.59% quarter-over-quarter from $5.9 million in Q3 2025.
Decoy Therapeutics (DCOY) Cash from Financing Activities (2015 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Cash from Financing Activities for 11 consecutive years, with $6.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 5775.68% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $11.8 million (up 563.13% YoY), while the FY2025 annual figure was $12.3 million, up 1064.0% from the prior year.
- Cash from Financing Activities climbed to $6.1 million in Q4 2025 per DCOY's latest filing, from $5.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $28.2 million in Q1 2021 and bottomed at -$358119.0 in Q2 2021.
- Historically, Cash from Financing Activities has averaged $2.6 million across 5 years, with a median of $31256.0 in 2021.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 16945000.0% — and 2025, when it jumped 5775.68%.
- Decoy Therapeutics' Cash from Financing Activities stood at $31256.0 in 2021, then slumped by 100.0% to $1.0 in 2022, then sank by 16945000.0% to -$169449.0 in 2023, then soared by 36.86% to -$106983.0 in 2024, then surged by 5775.68% to $6.1 million in 2025.
- Business Quant data shows DCOY's Cash from Financing Activities at $6.1 million in Q4 2025, $5.9 million in Q3 2025, and -$141197.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.16 Mn |
| Jun 30, 2026 | 3.16 Mn |
| Dec 31, 2025 | 6.07 Mn |
| Dec 31, 2025 | 6.07 Mn |
| Sep 30, 2025 | 5.86 Mn |
| Sep 30, 2025 | 5.86 Mn |
| Jun 30, 2025 | -141,197.00 |
| Jun 30, 2025 | -141,197.00 |
| Mar 31, 2025 | 545,566.00 |
| Mar 31, 2025 | 545,566.00 |
| Dec 31, 2024 | -106,983.00 |
| Dec 31, 2024 | -106,983.00 |
| Sep 30, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | -28,190.00 |
| Jun 30, 2024 | -28,190.00 |
| Mar 31, 2024 | -172,750.00 |
| Mar 31, 2024 | -172,750.00 |
| Dec 31, 2023 | -169,449.00 |
| Dec 31, 2023 | -169,449.00 |